News

Boston Scientific (NYSE:BSX), a medical-device maker for interventional specialties, closed Wednesday at $75.50, down 17.59%. The stock fell after Q4 earnings beat expectations, but cautious 2026

It has been an unfortunate past few years for one of the country's largest healthcare companies, UnitedHealth Group (NYSE: UNH). There has been no shortage of bad PR, a changing business landscape

Nvidia (NASDAQ: NVDA) has been one the biggest success stories in the stock market. After having spent the first 20 years of its existence as a publicly traded company producing solid but not

Eli Lilly's (NYSE: LLY) share price jumped 39% in 2025, driven by investors eager to benefit from the success of the company's GLP-1 drugs, Mounjaro (for diabetes) and Zepbound (for weight loss)

Shares of pharmaceutical giant Pfizer (NYSE: PFE) have been crashing for multiple years. The last time it posted a positive gain was in 2021, when it rose by more than 60%. Back then, business was

UnitedHealth Group (NYSE: UNH) is a stock that looks to be in deep trouble. As of the end of January, it was already down 13% in 2026. And that's after an already brutal year in 2025, when it fell

Novo Nordisk (NYSE:NVO), a diabetes and obesity drug maker, closed Tuesday at $50.33, down 14.59%. The stock sold off after management projected a 2026 sales and profit decline despite strong recent

Obesity is a global health crisis and is a direct or indirect cause of various health conditions. The emergence of GLP-1 agonists over the past several years has ignited one of the most significant

Healthcare stocks are not known for healthy dividends. Great for growth, yes, but often so-so for dividend yields. The average medical large-cap stock's dividend yield was 1.67% at the end of 2025

The story of Nvidia's (NASDAQ: NVDA) ascent to become the most valuable stock in the world has dominated headlines for the past several years. But what many investors may not realize is that the

Over the past five years, Axsome Therapeutics (NASDAQ: AXSM) has been on fire. The company has crushed the market in this period on the back of solid clinical and regulatory progress. At this point

Pfizer (NYSE: PFE) stock gave up 3.3% through 10:50 a.m. ET Tuesday despite delivering an earnings beat this morning.

Analysts forecast the pharmaceuticals giant would earn $0.57 per share on $16.8

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other AI stocks. To learn more, check out the short video, consider subscribing, and click the special

Hindsight is perfect. It's easy now to look back and think that artificial intelligence chip pioneer Nvidia (NASDAQ: NVDA) was always destined for greatness, given that it now has the largest market

Shares of Abbott Laboratories (NYSE: ABT) recently plunged after the company announced its fourth-quarter results. Over the trailing 12 months, the stock is down 16%. Some might choose to stay away

Pfizer (NYSE: PFE) is one of the world's largest pharmaceutical companies. It has a long history of innovation and success. Add in a lofty 6.6% dividend yield, and dividend investors are likely to

In some ways, AbbVie (NYSE: ABBV) isn't the same company it was five years ago. Sure, it's still in the biopharmaceuticals business. However, AbbVie has a new CEO. More importantly, it no longer

Shares of AT&T (NYSE: T) jumped more than 10% this past week, according to data from S&P Global Market Intelligence.

The wireless carrier delivered an impressive quarterly financial report and

Last month, millions of people made New Year's resolutions. Many of them have likely already come to a halt. But the experiment I started on Jan. 1 is still going strong, and as the new Voyager

Pfizer (NYSE: PFE) got a huge boost during the coronavirus pandemic thanks to its COVID-19 vaccine. Since that point, however, investors have soured on the stock, which has lost more than half its

Over the past decade, AbbVie (NYSE: ABBV) and Mastercard (NYSE: MA) have produced strong market returns. Their performance is even better once we account for dividends reinvested. That is one of the

John Walter Hanna Jr., President and CEO of CareDx (NASDAQ:CDNA), directly sold 19,480 shares in multiple open-market transactions on Jan. 21 and Jan. 22, 2026, for a total value of approximately

Over the last three years, OpenAI and Anthropic have evolved from speculative artificial intelligence (AI) laboratories into full-blown infrastructure behemoths. Between the two companies, trillions

In the volatile biotech industry, companies can see their shares soar over relatively short periods on strong clinical progress for exciting pipeline candidates.

That's precisely what could happen

Marc Stapley, a director at Glaukos Corporation (NYSE:GKOS), executed a direct sale of 15,000 shares for a transaction value of approximately $1.9 million on Jan. 22, 2026, following the exercise of